Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
Date:5/8/2008

NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial is being conducted under the direction of Ellen K. Ritchie, M.D. at The Weill-Cornell Medical College in New York City. Co- investigators for the study are Eric Feldman, M.D. and Gail Roboz, M.D.

The objectives of the trial are: (i) to define the maximum tolerated dose (MTD) of Cloretazine(R) (VNP40101M) when given in combination with cytarabine to AML and high-risk MDS patients over the age of 60, and (ii) to evaluate this combination further for safety and efficacy in a larger cohort of patients. Cloretazine(R) (VNP40101M) will be given as a 30 - 60 minute infusion on day 1 approximately 3-4 hours after the start of the cytarabine infusion. Cytarabine will be administered as a continuous infusion of 100 mg/m2/day for 7 days. In the Phase I portion of the study, dose escalation will be done in cohorts of at least 3 patients and the maximum tolerated dose (MTD) identified in the Phase I segment will be used in the Phase II segment of the study.

Ann Cahill, Vice President, Clinical Development, commented, "It is important for us to continue to study Cloretazine(R) (VNP40101M) in combination with different doses and schedules of cytarabine, the most widely used drug in the treatment of AML. In addition, we want to evaluate Cloretazine(R) (VNP40101M) in a broader group of elderly patients than are currently being studied in our pivotal tri
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
8. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
9. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Inc. (Nasdaq: MSON ), a developer of minimally invasive ... the ablation of tumors and worldwide for other acute health ... year ended June 30, 2009. , The Company also reported ... payment of $3.5 million was received on April 7, 2009 ...
... , SAN MATEO, Calif., Oct. 1 Corthera Inc. ... (FDA) has granted Fast Track designation to relaxin, the ... failure (AHF). The Fast Track program facilitates the development ... treat serious or life-threatening conditions and that demonstrate the ...
Cached Medicine Technology:Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 8Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 9Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 10Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 2Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 3
(Date:10/22/2014)... Hay House is pleased to announce the official ... Life (Paperback; $10.82) written by the highly esteemed Tommy Rosen, ... book is meant to help readers of all kinds end ... , Recovery 2.0 is not the average self-help book, or ... guide for what comes next. For many, Alcoholics ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Two sisters in high ... damage. Ilina and Medha Krishen use electronic stethoscopes, ... of trouble in breathing patterns or heartbeats. Ilina, ... Michigan, wanted to find a way to detect early ... Using an electronic stethoscope, Ilina recorded one breath cycle ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. ... officially tightened guidelines for health workers treating Ebola patients, now ... of a respirator at all times. The U.S. Centers ... rules after two Dallas nurses contracted Ebola while caring for ... national Thomas Eric Duncan. Nina Pham is currently being treated ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... sees telcos looking to find,viable solutions for improving public safety and network resiliency for all ... Americans, BOULDER, Colo., April 3, 2008 , WHO: ... Aztek Networks ( http://www.azteknetworks.net ), ... 20 years experience, Bruny has served as CEO of Aztek Networks, ...
... Rhytec, Inc. the pioneer,of plasma skin regeneration ... a novel thermal energy called plasma for reversing ... U.S. Food and Drug Administration (FDA),clearance to market ... is already cleared by the FDA for treating ...
... a,statement of William V. Corr, Executive Director, Campaign for ... broken Ohio,s,promise to protect its kids from tobacco by ... tobacco prevention program, run by the,Ohio Tobacco Prevention Foundation. ... carried out. More kids will become addicted to tobacco, ...
... Grubb &,Ellis Healthcare REIT, Inc. today announced the acquisition ... 3035, 3037, 3131, and 3133 Lakeland Hills Blvd., the ... buildings. Each,building has approximately 8,000 square feet of gross ... 1998 on approximately 4.64,acres, the buildings are cumulatively 90 ...
... Roy Blunt (Mo.) issued the following statement today after ... global AIDS initiative -,even though the president himself only ... the program couldn,t spend in 10,years what the majority ... more than one occasion that the president,s initiative on,fighting ...
... Disease Patients Rising, CHICAGO, April 2 ... disease and, according to the latest research,from Prevent ... number,is continuing to climb. With more than 130 ... million suffer from leading causes of vision loss ...
Cached Medicine News:Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 2Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 3Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 2Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 3Health News:Gov. Strickland, Legislative Leaders Break Promise to Protect Ohio's Kids from Tobacco 2Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 2Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 3Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 4Health News:Eye Disease Continuing to Increase Among Americans 2Health News:Eye Disease Continuing to Increase Among Americans 3
... Flexible excellence for patients and clinicians., ... Aestiva/5 anesthesia system, the Aestiva/5 MRI is ... systems with a fully functional, integrated ventilator. ... Gauss, 1.5 T active shielded magnet), the ...
... ventilator control panel is conveniently located on the ... angle whether standing or sitting. The ventilator control ... and numerics. The ventilator has CMV, PCV and ... available in two lengths facilitates both the placing ...
... The flexible, modular approach to meeting today's ... offers one of the best ergonomic solutions in ... to operate from any position. A revolving arm ... magazine and moveable patient cassette mean that there ...
... The Narkomed GS provides high quality ... interface. The proven technologies of the ... make the Narkomed GS user-friendly and ... high quality Narkomed GS is the ...
Medicine Products: